The article, Stool Processing Method Might Be Important for Efficacy in Fecal Transplantation Protocols, published on January 15, 2019, contained the incorrect statement, “FMT is FDA approved to treat refractory Clostridium difficile infection,” which has been corrected to “FMT is considered investigational by the FDA for treating refractory Clostridium difficile infection.”
The summary has been revised and republished here.
We apologize to our readers.